ISELIN, N.J. - Outlook Therapeutics, Inc. (NASDAQ:OTLK), a clinical-stage biopharmaceutical company with a current market capitalization of $52 million, reported at the Hawaiian Eye and Retina 2025 ...
It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...
Lucentis' main patents are not due to expire in Europe until next year, but Samsung Bioepis and Biogen are now poised to roll out the drug as soon the intellectual property on the drug lapses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback